Improved Quality of Life for Head and Neck Cancer Patients with Nivolumab
Nivolumab (Opdivo) improved quality of life scores in most patients with head and neck squamous cell carcinoma (HNSCC).
Institute for Clinical Immuno-Oncology (ICLIO) Delivers Immunotherapy Education in the Community Setting
The Insitute for Clinical Immuno-Oncology (ICLIO) are supporting multidisciplinary cancer teams to better deliver new and emerging cancer therapies.
A Targeted Role for Pembrolizumab to Treat Certain Solid Tumors
Pembrolizumab (Keytruda) has been granted accelerated approval for certain solid tumors.
Pembrolizumab Now FDA-Approved for Urothelial Carcinoma
The FDA has granted approval to pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Frontline Pembrolizumab Approved for NSCLC
The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with non-small cell lung cancer (NSCLC).
Rajni Kannan on Managing Patients on Combination Immunotherapy
Rajni Kannan, BS, MS, RN, APN-BC, discusses the management of patients receiving combination immunotherapy.
Another Immunotherapy Drug, Avelumab, Approved to Treat Bladder Cancer
The FDA has granted accelerated approval to avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Closing the Immunotherapy Knowledge Gap With Technology
Nurses at Smilow Cancer Hospital leveraged their electronic medical record system to improve care and management of patients receiving immunotherapies.
Higher Ipilimumab Dose Benefits Some Melanoma Patients, but Toxicity a Factor
While patients with stage III or IV melanoma who received a higher dose of ipilimumab did live longer than those on a lower dose, there was also greater toxicity.
Jose Lutzky on Proactively Monitoring Patients Receiving Immunotherapy Treatments
Jose Lutzky, MD, discusses the importance of proactive patient monitoring with patients receiving immunotherapy treatments.
Immunotherapy Emerging as Potential Option for Mesothelioma
A recent study has found that pembrolizumab (Keytruda) may be effective in treating patients with mesothelioma.
Novel Immunotherapy Under Study in Pancreatic Cancer
An ongoing trial is evaluating the combination therapy of interleukin-10 agonist AM0010 and FOLFOX chemotherapy, for patients with metastatic pancreatic cancer.
Richard Carvajal on Multidisciplinary Approach to Managing Immunotherapy Toxicities
Richard Carvajal, MD, discusses the importance of a multidisciplinary approach when monitoring patients for immunotherapy toxicities.
Immunotherapy Combination Shows Promise in Advanced Ovarian Cancer
After chemotherapy proved unsuccessful, one patient entered a clinical trial of a new combination for immunotherapy for her ovarian cancer.
Practical Guide on the Use of Immunotherapy in Melanoma
Long-Term NSCLC Survival Could Be 25% With Pembrolizumab
For patients with non-small cell lung cancer (NSCLC) receiving pembrolizumab, long-term survival rates could reach 25%.
Using Antibiotics Could Affect Checkpoint Inhibitors
A recent study presented at the 2017 Genitourinary Cancers Symposium found that use of antibiotics could damper the efficacy of checkpoint inhibitors, potentially due to the relationship between gut microbiota and antibiotics.
Some Patients Still Respond After Stopping Immunotherapy for Kidney Cancer Due to irAEs
Some patients with metastatic rena cell carcinoma (mRCC) exhibited sustained responses even up to 6 months of being off the immunotherapy treatment.
Richard Carvajal on Immunotherapy Dosing
Richard Carvajal, MD, discusses how to make decisions regarding the dosing limits of immunotherapy agents.
ASCO's Advance of the Year is Immunotherapy 2.0
The American Society of Clinical Oncology named Immunotherapy 2.0 as the Advance of the Year, as it continues to move the cancer field forward.
Claire Friedman on Considerations for Older Patients Receiving Immunotherapy
Claire Friedman discusses the factors clinicians should consider when determining an immunotherapy treatment plan for older patients.
Laura Wood on Multidisciplinary Collaboration for Managing Immunotherapy Adverse Events
Laura Wood on collaboration between departments when treating patients with cancer who are receiving immunotherapy treatments.
Karen Lee on Explaining Immunotherapy for Patient Education
Karen Lee explains why it is important for patients to understand immunotherapy and how nurses can help them in patients education.
Immunotherapies Changing Treatment Landscape and Outcomes in Head and Neck Cancer
Immunotherapy agents are drastically changing the treatment landscape – and outcomes – of patients with head and neck cancers.
Managing Complex Immune-Related Adverse Events: Talking with Nurse Practitioner Brianna Hoffner
Nurse practitioner Brianna Hoffner, MSN, NP, RN, discusses the important things to consider for an oncology nurse working with patients being treated with cancer immunotherapies.
Lisa Butterfield on the Nurse's Role in Immunotherapy Treatment
Lisa Butterfield discusses what nurses should know when treating patients receiving immunotherapies.
Alex Herrera on Nivolumab/Brentuximab Vedotin Combination for Patients with Hodgkin Lymphoma
Alex Herrera discusses the response of patients with Hodgkin lymphoma on combination nivolumab/brentuximab vedotin.
Igor Puzanov on Monitoring Cardiologic Toxicities from Checkpoint Inhibitors
Igor Puzanov discusses the rare cardiologic adverse events that can occur when a patient is on checkpoint inhibitors.
Elizabeth Repasky Explains the Effect of Chronic Stress on Anti-Tumor Immune Responses
Elizabeth Repasky discusses chronic stress and its link to anti-tumor immune reponses.
Christian Capitini on Response to Immunotherapy
Christian Capitini discusses the responses to immunotherapy.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer